In addition, tamoxifen, a selective ER modulator [279], has been identified to enhance the stemness and metastasis of breast cancer by upregulating aldehyde dehydrogenase 1A1 (ALDH1A1) transcription in cancer cells through direct binding to and activation of ERα36 [280]. Here, ALDH1A1 is linked to breast cancer.